PMID- 29519701
OWN - NLM
STAT- MEDLINE
DCOM- 20190314
LR  - 20211204
IS  - 1873-2615 (Electronic)
IS  - 1050-1738 (Linking)
VI  - 28
IP  - 6
DP  - 2018 Aug
TI  - Translational overview of cytokine inhibition in acute myocardial infarction and 
      chronic heart failure.
PG  - 369-379
LID - S1050-1738(18)30016-1 [pii]
LID - 10.1016/j.tcm.2018.02.003 [doi]
AB  - Many cytokines are currently under investigation as potential target to improve 
      cardiac function and outcome in the setting of acute myocardial infarction (MI) 
      or chronic heart failure (HF). Here we aim to provide a translational overview of 
      cytokine inhibiting therapies tested in experimental models and clinical studies. 
      In various experimental studies, inhibition of interleukin-1 (IL-1), -6 (IL-6), 
      -8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), CC- and CXC chemokines, 
      and tumor necrosis factor-alpha (TNF-alpha) had beneficial effects on cardiac function 
      and outcome. On the other hand, neutral or even detrimental results have been 
      reported for some (IL-1, IL-6, IL-8, and MCP-1). Ambivalence of cytokine 
      function, differences in study designs, treatment regimens and chosen endpoints 
      hamper the translation of experimental research into clinical practice. Human 
      studies are currently limited to IL-1beta inhibition, IL-1 receptor antagonists 
      (IL-1RA), IL-6 receptor antagonists (IL-6RA) or TNF inhibition. Despite favorable 
      effects on cardiovascular events observed in retrospective cohort studies of 
      rheumatoid arthritis patients treated with TNF inhibition or IL-1RA, most 
      prospective studies reported disappointing and inconsistent results. Smaller 
      studies (n < 100) generally reported favorable results of anticytokine therapy on 
      cardiac function, but only one of the larger studies (n > 100) evaluating IL-1beta 
      inhibition presented positive results on outcome. In conclusion, of the 10 
      anticytokine therapies tested in animals models beneficial effects have been 
      reported in at least one setting. In larger clinical studies, findings were 
      unsatisfactory in all but one. Many anticytokine therapies with promising animal 
      experimental data continue to require further evaluation in humans.
CI  - Copyright (c) 2018 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Hartman, Minke H T
AU  - Hartman MHT
AD  - Department of Cardiology, University of Groningen, University Medical Center 
      Groningen, Hanzeplein 1, 9700 RB, Groningen, the Netherlands. Electronic address: 
      h.t.hartman@umcg.nl.
FAU - Groot, Hilde E
AU  - Groot HE
AD  - Department of Cardiology, University of Groningen, University Medical Center 
      Groningen, Hanzeplein 1, 9700 RB, Groningen, the Netherlands.
FAU - Leach, Irene Mateo
AU  - Leach IM
AD  - Department of Cardiology, University of Groningen, University Medical Center 
      Groningen, Hanzeplein 1, 9700 RB, Groningen, the Netherlands.
FAU - Karper, Jacco C
AU  - Karper JC
AD  - Department of Cardiology, University of Groningen, University Medical Center 
      Groningen, Hanzeplein 1, 9700 RB, Groningen, the Netherlands.
FAU - van der Harst, Pim
AU  - van der Harst P
AD  - Department of Cardiology, University of Groningen, University Medical Center 
      Groningen, Hanzeplein 1, 9700 RB, Groningen, the Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180215
PL  - United States
TA  - Trends Cardiovasc Med
JT  - Trends in cardiovascular medicine
JID - 9108337
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Cytokines)
RN  - 0 (Inflammation Mediators)
SB  - IM
CIN - Trends Cardiovasc Med. 2018 Aug;28(6):380-381. PMID: 29661709
MH  - Animals
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Cytokines/*antagonists & inhibitors/immunology
MH  - Heart Failure/*drug therapy/immunology/physiopathology
MH  - Humans
MH  - Inflammation Mediators/*antagonists & inhibitors/immunology
MH  - Myocardial Infarction/*drug therapy/immunology/physiopathology
MH  - Signal Transduction/drug effects
MH  - Translational Research, Biomedical
OTO - NOTNLM
OT  - Cytokines
OT  - Heart failure
OT  - Immune modulation/therapy
OT  - Inflammation
OT  - Myocardial infarction
EDAT- 2018/03/10 06:00
MHDA- 2019/03/15 06:00
CRDT- 2018/03/10 06:00
PHST- 2017/11/05 00:00 [received]
PHST- 2018/02/05 00:00 [revised]
PHST- 2018/02/05 00:00 [accepted]
PHST- 2018/03/10 06:00 [pubmed]
PHST- 2019/03/15 06:00 [medline]
PHST- 2018/03/10 06:00 [entrez]
AID - S1050-1738(18)30016-1 [pii]
AID - 10.1016/j.tcm.2018.02.003 [doi]
PST - ppublish
SO  - Trends Cardiovasc Med. 2018 Aug;28(6):369-379. doi: 10.1016/j.tcm.2018.02.003. 
      Epub 2018 Feb 15.